|
| Effect of Qili Qiangxin Capsule for heart failure with preserved ejection fraction on quality of life:a meta-analysis |
| Hits 570 Download times 454 Received:December 16, 2021 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2022.03.14 |
| Key Words
Qili Qiangxin Capsule;ejection fraction preserved heart failure;meta-analysis;systematic review;GRADE |
| Author Name | Affiliation | E-mail | | GE Zhao | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LIU Chunxiang | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LIN Shanshan | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Xianliang | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | xlwang1981@126.com | | MAO Jingyuan | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | |
|
| Abstract
|
| [Objective] To systematically evaluate the effect of Qili Qiangxin Capsule combined with conventional western medicine on quality of life in patients with ejection fraction preserved heart failure (HFpEF). [Methods] Clinical randomized controlled trials (RCTs) of Qili Qiangxin Capsule for treating preserved heart failure were systematically identified in electronic databases including CNKI,Wanfang,VIP,SinoMed,PubMed,Embase,and Cochrane Library. The Cochrane's risk of bias tool was used to evaluate the methodological quality of the included studies,the RevMan 5.3 software was used for meta-analysis,the Stata 15.0 software was used to evaluate publication bias,and the quality of evidence was graded according to the guidelines of the Grading of Recommendations Assessment,Development and Evaluation (GRADE) system. [Results] A total of 26 RCTs involving 2 221 patients were finally included. The study showed that,compared with conventional therapy alone,Qili Qiangxin Capsule combined with conventional therapy has a statistically significant difference in comprehensive clinical efficacy(RR=1.24,95%CI[1.18,1.31],P<0.000 01),therapeutic effect of traditional Chinese medicine syndrome (RR=1.18,95%CI[1.05,1.32],P=0.005),quality of life(WMD=-8.70,95%CI[-10.24,-7.17], P<0.0001),6 min walking distance (WMD=58.78,95%CI[38.79,78.76],P<0.000 01),left ventricular ejection fraction (WMD=4.06, 95%CI[3.12,5.00],P<0.000 01),E/e'(WMD=-2.70,95%CI[-3.52,-1.88],P<0.000 01),LAVI (WMD=58.78,95%[38.79,78.76],P<0.000 01) in patients with preserved ejection fraction on quality of life heart failure;there is no significant difference in drug-related adverse reactions. According to GRADE standard,quality of life,E/e',LAVI and incidence of adverse reactions were medium quality evidence,comprehensive clinical efficacy,therapeutic effect of traditional Chinese medicine syndrome,6 min walking distance and left ventricular ejection fraction were low-quality evidence. [Conclusion] Qili Qiangxin Capsule combined with conventional Western medicine treatment can improve the quality of life of HFpEF patients,there is no significant difference in drug-related adverse reactions.However,due to the low quality of evidence,the end-point indicators are less concerned. |
|
|
|
|
|
|
|
